EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Severity of acute SARS-CoV-2 infection and risk of new-onset autoimmune disease: A RECOVER initiative study in nationwide U.S. cohorts

Shannon Wuller iD, Nora G Singer, Colby Lewis iD, Elizabeth W Karlson, Grant S Schulert, Jason D Goldman iD, Jennifer Hadlock iD, Jonathan Arnold iD, Kathryn Hirabayashi, Lauren E Stiles iD, Lawrence C Kleinman, Lindsay G Cowell und 14 weitere

PLOS One · 04.06.2025 · 20 (6) · e0324513

DOI: 10.1371/journal.pone.0324513 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 04.06.2025. Verfasst von Shannon Wuller und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population Health, New York University Grossman School of Medicine, New York, New York, United States of America. Hauptthemen laut MEDLINE: COVID-19, Autoimmune Diseases. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, National Institute of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SARS-CoV-2 infection has been associated with increased autoimmune disease risk. Past studies have not aligned regarding the most prevalent autoimmune diseases after infection, however. Furthermore, the relationship between infection severity and new autoimmune disease risk has not been well examined. We used RECOVER’s electronic health record (EHR) networks, N3C, PCORnet, and PEDSnet, to estimate types and frequency of autoimmune diseases arising after SARS-CoV-2 infection and assessed how infection severity related to autoimmune disease risk. We identified patients of any age with SARS-CoV-2 infection between April 1, 2020 and April 1, 2021, and assigned them to a World Health Organization COVID-19 severity category for adults or the PEDSnet acute COVID-19 illness severity classification system for children (30 days after SARS-CoV-2 infection index date and occurring ≥1 day apart. We calculated overall and infection severity-stratified incidence ratesper 1000 person-years for all autoimmune diseases. With least severe COVID-19 severity as reference, survival analyses examined incident autoimmune disease risk. The most common new-onset autoimmune diseases in all networks were thyroid disease, psoriasis/psoriatic arthritis, and inflammatory bowel disease. Among adults, inflammatory arthritis was the most common, and Sjögren’s disease also had high incidence. Incident type 1 diabetes and hematological autoimmune diseases were specifically found in children. Across networks, after adjustment, patients with highest COVID-19 severity had highest risk for new autoimmune disease vs. those with least severe disease (N3C: adjusted Hazard Ratio, (aHR) 1.47 (95%CI 1.33–1.66); PCORnet aHR 1.14 (95%CI 1.02–1.26); PEDSnet: aHR 3.14 (95%CI 2.42–4.07)]. Overall, severe acute COVID-19 was most strongly associated with autoimmune disease risk in three EHR networks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Autoimmune DiseasesHumansFemaleMaleAdultUnited StatesMiddle AgedSeverity of Illness IndexChildSARS-CoV-2AgedAdolescentYoung AdultChild, PreschoolElectronic Health RecordsRisk FactorsCohort Studies

Autor:innen und Institutionen

  • Department of Population Health, New York University Grossman School of Medicine, New York, New York, United States of America.
  • Department of Rheumatology, The MetroHealth System, Cleveland, Ohio, United States of America.
  • Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America.
  • Department of Population Health Sciences, Weill Cornell Medical College, New York, New York, United States of America.
  • Department of Medicine, Division of Rheumatology, Inflammation and Immunity, Section of Clinical Sciences, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
  • Rheumatology and Allergy Clinical Epidemiology Research Center, Mongan Institute, Massachusetts General Hospital, Boston, Massachusetts, United States of America.

ORCID-Profile: Shannon Wuller, Colby Lewis, Jason D Goldman, Jennifer Hadlock, Jonathan Arnold, Lauren E Stiles, Mady Hornig, Mark G Weiner, Michael Koropsak, Richard A Moffitt, Sajjad Abedian

Förderung

  • NIDDK NIH HHS
  • NCATS NIH HHS
  • National Institute of Health

Zitieren

APA

Wuller, S., Singer, N. G., Lewis, C., Karlson, E. W., Schulert, G. S., Goldman, J. D., Hadlock, J., Arnold, J., Hirabayashi, K., Stiles, L. E., Kleinman, L. C., Cowell, L. G., Hornig, M., Hall, M. A., Weiner, M. G., Koropsak, M., Lamendola-Essel, M. F., Kenney, R., Moffitt, R. A., …, & RECOVER Initiative, RECOVER PCORnet EHR Cohort, and the N3C RECOVER EHR Cohort (2025). Severity of acute SARS-CoV-2 infection and risk of new-onset autoimmune disease: A RECOVER initiative study in nationwide U.S. cohorts. PLOS One, 20(6), e0324513. https://doi.org/10.1371/journal.pone.0324513

Vancouver

Wuller S, Singer NG, Lewis C, Karlson EW, Schulert GS, Goldman JD, et al. Severity of acute SARS-CoV-2 infection and risk of new-onset autoimmune disease: A RECOVER initiative study in nationwide U.S. cohorts. PLOS One. 2025;20(6):e0324513. doi:10.1371/journal.pone.0324513

BibTeX
@article{Wuller2025,
  author = {Wuller, Shannon and Singer, Nora G and Lewis, Colby and Karlson, Elizabeth W and Schulert, Grant S and Goldman, Jason D and Hadlock, Jennifer and Arnold, Jonathan and Hirabayashi, Kathryn and Stiles, Lauren E and Kleinman, Lawrence C and Cowell, Lindsay G and Hornig, Mady and Hall, Margaret A and Weiner, Mark G and Koropsak, Michael and Lamendola-Essel, Michelle F and Kenney, Rachel and Moffitt, Richard A and Abedian, Sajjad and Esquenazi-Karonika, Shari and Johnson, Steven G and Stroebel, Stephenson and Wallace, Zachary S and Costenbader, Karen H and RECOVER Initiative, RECOVER PCORnet EHR Cohort, and the N3C RECOVER EHR Cohort, RECOVER Initiative, RECOVER PCORnet EHR Cohort, and the N3C RECOVER EHR Cohort},
  title = {Severity of acute SARS-CoV-2 infection and risk of new-onset autoimmune disease: A RECOVER initiative study in nationwide U.S. cohorts},
  journal = {PLOS One},
  year = {2025},
  volume = {20},
  number = {6},
  pages = {e0324513},
  doi = {10.1371/journal.pone.0324513}
}
Kostenlos starten →